TL;DR
A systematic review and meta-analysis of five studies, involving nearly 24,000 women, found hormone therapy was associated with more frequent migraine attacks and longer episodes in postmenopausal women. The analysis did not find significant differences in migraine severity scores or monthly analgesic use; researchers say more evidence is needed to determine whether therapy itself affects migraines.
A review of five studies involving nearly 24,000 women found that postmenopausal women using hormone therapy had an association with more frequent migraine attacks and longer-lasting episodes. The findings, which do not establish that hormone therapy caused the changes, are scheduled for presentation at The Menopause Society’s annual meeting in San Diego, running October 20–24, 2026.
The researchers examined the relationship between hormone therapy and several migraine outcomes in postmenopausal women: whether migraines occurred, their severity, how often attacks happened, how long episodes lasted and how many pain-relief medicines were used. The analysis combined results from five studies, with nearly 24,000 women included overall. It reported a pooled mean migraine incidence of 18.94%.
The pooled findings associated hormone therapy with increased migraine frequency and longer episode duration. Researchers reported no significant differences in migraine severity scores or in the number of analgesics used per month. The source material does not provide the size of the observed frequency or duration differences, or enough detail to assess how those outcomes varied across the individual studies.
The work is titled “Impact of Hormone Replacement Therapy on Migraine Outcomes in Postmenopausal Women: A Systematic Review and Meta-Analysis.” Lead author Dr. Flavia Fairbanks Ruano of the University of Miami Miller School of Medicine said the researchers aimed to assess outcomes independently of the route of hormone administration. The results are being presented at a meeting; the source does not describe them as a completed clinical trial.
Balancing Menopause Relief and Migraine
Hormone therapy is used to ease menopause symptoms, particularly hot flashes. The reported association may matter to people weighing symptom relief against changes in migraine patterns, and to clinicians discussing treatment options with patients who experience migraines. But the analysis does not show that hormone therapy directly caused more attacks or longer episodes, so it should not be treated as proof that the treatment will worsen migraines for an individual.
The findings also do not report a significant change in migraine severity scores or monthly pain-relief medicine use. That distinction matters: frequency and duration are separate measures of migraine burden, and the available summary gives no effect sizes that would show how large the differences were. The results raise a question for further study rather than settling how the benefits and possible migraine effects compare for any particular patient.
For readers, the practical point is that migraine history may be relevant in conversations about menopause care, while treatment choices remain individual. The source material does not recommend stopping or avoiding hormone therapy. Anyone considering a change to treatment should discuss personal symptoms, risks and options with a qualified health professional rather than rely on this study summary alone.
As an affiliate, we earn on qualifying purchases.
Estrogen Changes and Migraine Patterns
Migraines are estimated to affect 10% to 29% of women during the menopause transition, according to the supplied report. Symptoms can change during this period and may become more frequent, particularly in perimenopause. The report links this pattern to unpredictable drops in estrogen, but that background does not by itself establish how hormone therapy affects migraines after menopause.
Hormone levels and treatment can be part of a complicated picture. The study’s stated aim was to examine associations between therapy and migraine outcomes in postmenopausal women, including across routes of administration. The authors’ pooled analysis draws on existing studies, rather than a single trial described in the source. That means the result is an association across the evidence reviewed, not a controlled demonstration that starting therapy produces a particular migraine outcome.
The report also notes that hormone therapy can be used for bothersome menopause symptoms and that many women with migraine may seek treatment for those symptoms. This is relevant to interpreting the comparison: women who use therapy may differ from those who do not in ways that affect migraine outcomes. The source does not provide enough information to determine how fully the underlying studies accounted for such differences.
“The researchers sought to evaluate the associations of hormone therapy with migraine outcomes, including incidence, severity, frequency, duration, and analgesic use in postmenopausal women, independently of the route of administration.”
— Dr. Flavia Fairbanks Ruano, lead author, University of Miami Miller School of Medicine
Cause and Size of the Difference
The supplied report does not give the exact increase in attack frequency or episode duration, confidence intervals, or study-by-study results. It also does not specify the treatment formulations, doses, duration of use, or how migraine outcomes differed by route. Without those details, readers cannot tell how large or consistent the observed associations were.
The findings do not establish whether hormone therapy caused the differences. As Faubion noted, women who seek menopause treatment may have underlying characteristics that distinguish them from women who do not. The report does not provide enough information to determine the extent to which the included studies addressed those possible differences. It also does not state whether the pooled result applies equally across different types of migraine or hormone therapy.
The reported lack of significant differences in severity scores and monthly analgesic use does not prove that those outcomes are identical between groups. It means the analysis, as summarized, did not identify significant differences on those measures. The study’s full methods and results, and any later clinical trials, will be needed to clarify the evidence.
Meeting Presentation and Further Trials
The review is scheduled for discussion at The Menopause Society’s annual meeting in San Diego from October 20 to 24, 2026, in a presentation bearing the study title. Further details about the methods, effect sizes and limitations may help clinicians and researchers judge how to interpret the association.
The report says further clinical trials are needed to better understand the relationship between hormone therapy and migraine and to guide treatment. Until more evidence is available, individual decisions should be made with a qualified clinician, taking account of menopause symptoms, migraine history and the person’s circumstances. The source does not identify a specific trial or timeline for additional research.
Key Questions
What did the review find about hormone therapy and migraines?
Across five studies involving nearly 24,000 women, hormone therapy was associated with more frequent migraine attacks and longer-lasting episodes in postmenopausal women. The analysis did not find significant differences in migraine severity scores or monthly analgesic use.
Does this prove hormone therapy causes migraines to worsen?
No. The review reported an association, which does not prove cause and effect. The report says more research is needed, including clinical trials, before drawing firm conclusions about hormone therapy’s effect on migraine burden.
Should someone with migraines avoid or stop hormone therapy?
The supplied findings do not recommend stopping or avoiding therapy. Hormone treatment decisions depend on individual circumstances and should be discussed with a qualified health professional. Do not change prescribed treatment based solely on this report.
When will the study be presented?
The findings are scheduled for presentation at The Menopause Society’s annual meeting in San Diego, October 20–24, 2026. The supplied report does not give a more specific presentation date or time.
Source: rss
